University of Wisconsin–Madison

Tag: treatment

Training for Clinical Trials with the IMPACT-AD Program

Posted on

Are you a researcher interested in getting involved in Alzheimer’s disease and related dementias (ADRD) clinical trials? The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD, or IMPACT-AD, program brings investigators from around the world together for a week of professional development and education. IMPACT-AD co-directors Dr. Josh Grill and Dr. Rema Raman, as well as faculty member Dr. Maria Carrillo, join the podcast to explain what the program entails, their mission and more.

Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, professor, University of California, Irvine (UCI), co-director, IMPACT-AD, Rema Raman, PhD, co-director, IMPACT-AD, director, Biostatistics Section and Recruitment, Engagement, and Retention Section, Alzheimer’s Therapeutic Research Institute (ATRI), professor of neurology, University of Southern California (USC), and Maria Carrillo, PhD, chief science officer, medical affairs lead, Alzheimer’s Association, co-principal investigator, Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), co-principal investigator, Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)

Could Managing Four Common Health Conditions Slow Cognitive Decline from Alzheimer’s?

Posted on

Alzheimer’s disease isn’t always the only health condition a person faces, so how does treating other diseases impact the progression of Alzheimer’s? Researchers at the University of Arizona focused on four common health conditions – type two diabetes, hypertension, inflammation and dyslipidemia – which are known to increase the risk of developing Alzheimer’s disease, and set out to investigate whether those diagnosed with Alzheimer’s who received treatments for these four conditions also saw a delay in cognitive decline. Dr. Barb Bendlin joins the podcast to break down the findings from this research, as well as discuss the impact of personalized prevention strategies and combination therapies.

Guest: Barbara Bendlin, PhD, professor, Division of Geriatrics and Gerontology, University of Wisconsin (UW) School of Medicine and Public Health, deputy director, UW Center for Health Disparities Research (CHDR)

Taking a Closer Look at Cognitive Decline and Preclinical Alzheimer’s Disease

Posted on

Dr. Reisa Sperling returns for another episode of Dementia Matters. After covering her research focused on preclinical Alzheimer’s disease in part one, Dr. Sperling dives deeper into the different factors that can impact cognitive decline and early-stage Alzheimer’s disease and how clinical trials are shaping the field’s understanding of detecting, treating and preventing the disease.

Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School

Defining and Addressing Preclinical Alzheimer’s Disease

Posted on

What if there was a way to detect Alzheimer’s disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer’s disease at the earliest possible stage, known as preclinical Alzheimer’s. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies for Alzheimer’s disease.

Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School

REVEALing APOE Results: Making Genetic Disclosures in Alzheimer’s Research

Posted on

On this episode of Dementia Matters, Dr. Scott Roberts talks about disclosing genetic test results for APOE, a gene that can increase one’s likelihood of developing Alzheimer’s disease. While this information can be concerning, Dr. Roberts shares that it can empower individuals to take the necessary precautions to lower their risk of developing the disease. He discusses the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study, walks us through the APOE disclosure process and shares how it is evolving with the development of new Alzheimer’s treatments.

Guest: Scott Roberts, PhD, interim chair, professor of health behavior & health education, University of Michigan School of Public Health

Could Green Tea Hold the Key to New Alzheimer’s Treatments?

Posted on

Dr. Paul Seidler joins the podcast to discuss his recent study looking at the connection between molecules in green tea and tau proteins. He also discusses the impact those molecules have on preventing cognitive decline and how these findings could lead to new strategies for treating Alzheimer’s disease.

Guest: Paul Seidler, PhD, assistant professor, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences

Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment

Posted on

On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.

Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health

Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness

Posted on

On June 9, 2023, the Food and Drug Administration’s (FDA) advisory committee unanimously voted to approve lecanemab, moving the treatment one step closer to full FDA approval. In the lead up to the FDA’s official announcement expected in early July, Dr. Paul Aisen joins the podcast to discuss Alzheimer’s disease clinical trials. Aisen,  the founding director of the Alzheimer’s Therapeutic Research Institute (ATRI) and a leading figure in Alzheimer’s disease research for over three decades, talks about the Phase 3 clinical trials for lecanemab and gantenerumab and shares highlights from the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Guest: Paul Aisen, MD, professor of neurology, Keck School of Medicine, University of Southern California, Director, Alzheimer’s Therapeutic Research Institute

A Closer Look At The Lecanemab Clinical Trials

Posted on

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023.

Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute

Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

Posted on

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

Breaking Down Medicare’s Proposed Decision on Aducanumab and Monoclonal Antibody Treatments

Posted on

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.

Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania

How Close Are We to Curing Alzheimer’s Disease?

Posted on

For our 100th episode of Dementia Matters, Nina Silverberg, PhD, director of the Alzheimer’s Disease Research Centers (ADRC) Program at the National Institute on Aging (NIA), joins the podcast to offer an overview of the ADRC Program as well as insight into the state of Alzheimer’s Disease research and its future. The NIA funds more than 30 Alzheimer’s Disease Research Centers across the country, including the Wisconsin ADRC.

Guest: Nina Silverberg, PhD, National Institute on Aging

When Good Becomes Bad: Researching the Impact of Neuroinflammation

Posted on

Inflammation is a common response throughout the body that fights injury and infection and works to rebuild cells after damage. Inflammation works the same way in the brain, but sometimes the inflammatory response meets damage it can’t manage and becomes dysregulated. Our guest Dr. Linda Van Eldik discusses her research into the connections between neuroinflammation and neurodegenerative diseases like dementia, and how this research can help inform the medical community about drug-based treatments for Alzheimer’s disease.

Guest: Dr. Linda Van Eldik, Director, Sanders-Brown Center on Aging

The Evolving Definition of Alzheimer’s Disease

Posted on

Alzheimer’s disease researchers are developing new techniques for identifying the disease much earlier than was possible in the past. This requires patients, families, and the medical community to talk about Alzheimer’s disease and dementia in different ways. Our guest Dr. Jason Karlawish joins us to discuss the evolving definitions of Alzheimer’s disease and dementia, as well as the ethical and social issues people with dementia face.

Guest: Dr. Jason Karlawish, Penn Memory Center, Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania